Introduction of biosimilars: not to be confused with generics

Generic versions of branded medicines have been with us for a long time – there was a proliferation of generic versions of aspirin, for example, when Bayer’s patent expired in 1917. We will all be familiar with the process through which generics are introduced to the market: the originator brand product has a finite patent life, at the end of which other manufacturers can apply for a licence to manufacture and market a generic version.

Introduction of biosimilars not to be confused with generics

Add yours ↓
Web design and marketing agency Leamington Spa